Respiratory failure & ventilation
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*
Authors' conclusion
Treatment with astegolimab or efmarodocokin alfa did not improve time to recovery in patients with severe COVID-19 pneumonia.
Study context
- Population
- Hospitalised adults with severe COVID-19 pneumoniarandomised
- Participants
- 396 adults
- Comparison
- IV astegolimab or efmarodocokin alfa vs placebo, plus standard of care
- Primary endpoint
- Time to recovery (score of 1 or 2 on a 7-category ordinal scale)
- Follow-up
- Day 28
Methodological detailsPhase 2, double-blind, placebo-controlled
- Phase 2
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Time to recovery
Hazard ratio
1.01
P = 0.93
Astegolimab
Hazard ratio
1.15
P = 0.38
Efmarodocokin alfa
Secondary outcomes
Key secondary endpoints (improved recovery, mortality, prevention of worsening)
- No treatment benefits
Biomarkers
- Both drugs pharmacologically active
Safety
Adverse events
- No new safety signals; AEs similar across arms
Original publication
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*. Crit Care Med. Published 14 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →